Will US anti-bribery actions be next in the China corruption affair?
This article was originally published in SRA
Drug makers embroiled in the recent bribery allegations in China are likely sweating over whether the next shoe to drop will be US charges under the Foreign Corrupt Practices Act (FCPA), given the Security and Exchange Commission has not been shy in the past from going after publicly traded biopharmas the agency determines has violated the law.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.